0001193125-18-111668.txt : 20180509 0001193125-18-111668.hdr.sgml : 20180509 20180409171955 ACCESSION NUMBER: 0001193125-18-111668 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aerpio Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001422142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 9987 CARVER ROAD CITY: CINCINNATI STATE: OH ZIP: 45242 BUSINESS PHONE: (513) 985-1920 MAIL ADDRESS: STREET 1: 9987 CARVER ROAD CITY: CINCINNATI STATE: OH ZIP: 45242 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP II DATE OF NAME CHANGE: 20071227 CORRESP 1 filename1.htm Acceleration request

Aerpio Pharmaceuticals, Inc.

9987 Carver Road

Cincinnati, OH 45242

April 9, 2018

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

  Re: Aerpio Pharmaceuticals, Inc. (the “Company”)
       Acceleration Request for Registration Statement on Form S-3
       File No. 333-223113

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on April 11, 2018, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Danielle Lauzon at (617) 570-1955. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Securities Act.

 

Very truly yours,

 

Aerpio Pharmaceuticals, Inc.

By:   /s/ Stephen Hoffman

Name:

Title:

  

Stephen Hoffman

Chief Executive Officer

cc: Goodwin Procter LLP